Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review

• DOI: 10.1002/onco.13923
• Publication Date: 2021-08-03T08:06:21Z
• Authors: David L. Chan; Emily K. Bergsland; Jennifer A. Chan; Rujuta Gadgil; Thorvardur R. Hal...; Kathleen Hornbacker; Virginia Kelly; Pamela L. Kunz; Patrick W. McGarrah; Nitya P. Raj; Diane L. Reidy; Alia Thawer; Julia Whitman; Linda Wu; Christoph Becker; Simron Singh
• Keywords: Temozolomide; Discontinuation; Regimen; Clinical endpoint

Grade 3 gastroenteropancreatic neuroendocrine neoplasms (G3 GEPNENs) are often aggressive, and the optimal treatment is unclear for this subgroup of (NENs). Temozolomide (TEM)-based regimens have been increasingly used to treat grade 1-2 NENs, but their efficacy in G3 NENs remains undetermined. We aimed assess clinical TEM-containing advanced GEPNENs.